Cannabidiol for young people at high risk for psychosis
Treatments studied
Part of Mental health clinical trials.
This study tests whether a medication called cannabidiol (a non-intoxicating compound from cannabis) can help reduce symptoms and prevent progression in young people at clinical high risk for psychosis. Participants will receive either the study drug or a placebo (a pill with no active ingredient) and will be followed to see how they respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 35 years old.
- You must have symptoms like mild or brief psychotic-like experiences (such as unusual thoughts or seeing/hearing things that aren't there) that are not a full psychotic episode.
- You must be willing to take an experimental medication (cannabidiol, a compound from cannabis that does not cause a high) for the study period, and if you are female and able to have children, use highly effective birth control.
- You cannot have had a previous full episode of psychosis, except for brief limited symptoms.
- You cannot have taken certain antipsychotic medications recently or for long periods, and you must not be taking certain other drugs (like valproate or clobazam).
- You must be able to attend safety checks (blood tests, pregnancy tests, reporting side effects) and have no medical conditions that would make the study unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MT1988 in people who show early warning signs of psychosis. Researchers want to see if it changes certain markers in the body related to mental health.
This trial tests a telehealth (video/phone) version of cognitive behavioral therapy to help young people who are at risk for developing psychosis. It may help by teaching skills to reduce symptoms and improve coping, with support from a key family or close person.
This study explores how young people who are at high risk for psychosis or have had a first episode experience mindfulness. It uses interviews to understand their personal experience, which could help improve future treatments.
This study tests whether a mindfulness program can help prevent psychosis in young people who are at ultra high risk. The goal is to see if learning mindfulness skills can protect your mental health and keep symptoms from getting worse.
This study uses brain imaging to look at dopamine activity in people at high risk for psychosis. The results may help improve future treatments.
This study tests a new program to help young people who have early signs of psychosis and have had thoughts of suicide or tried to harm themselves. The program works with the young person and a family member or caregiver to improve support and reduce suicide risk.
Hear when a new Clinical High Risk for Psychosis (CHR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.